Secukinumab's Pooled and Long-Term Safety: Analysis of 19 Psoriasis Clinical Trials Up to 5 Years of Treatment

PCM van de Kerkhof; Kristian Reich; C Leonardi; Andrew Blauvelt; Nehal Nailesh Mehta; TF Tsai; R. You; Phil Papanastasiou; M. Milutinovic; Christopher Em Griffiths

doi:10.25251/skin.2.supp.18

Related publications

Article2018

Maintenance of Response With Guselkumab for up to 3 Years’ Treatment in the Phase 3 VOYAGE 1 Trial of Patients With Plaque Psoriasis

Christopher Em Griffiths, KA Papp, Michael Song, B. Randazzo, S Li, Y-K Shen, Chenglong Han, Andrew Blauvelt

Article2020

Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials

Alice B. Gottlieb, Jashin J. Wu, Christopher Em Griffiths, Kwaku Marfo, Elisa Muscianisi, Xiangyi Meng, Jennifer Frueh, Mark Lebwohl

Article2016

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

P.C.M. van de Kerkhof, Christopher Em Griffiths, Kristian Reich, Craig L. Leonardi, Andrew Blauvelt, Tsen‐Fang Tsai, Yankun Gong, Jiaqing Huang, C. Papavassilis, Todd Fox

Article2021

28095 Long-term safety of guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials with up to 5 years of treatment

Andrew Blauvelt, Kenneth B. Gordon, Christopher Em Griffiths, Kim Papp, Peter Foley, Michael Song, Megan Miller, Yaung‐Kaung Shen, Paraneedharan Ramachandran, Kristian Reich

Article2013

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

Kim Papp, Christopher Em Griffiths, Kenneth B. Gordon, Mark Lebwohl, Philippe Szapary, Yasmine Wasfi, Daphne Chan, M.-C. Hsu, Vincent Ho, Pierre‐Dominique Ghislain, Bruce Strober, Kristian Reich